Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

A 26 year old female with PCOS who has been dealing with hair loss for several years, despite managing her hormones and taking vitamins. She has tried various treatments such as Nizoral, Minoxidil, Pyrithione zinc, coal tar and salicylic acid to no avail. The user is looking for advice on what else they can do to stop their hair loss.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

Lactic acid is not effective for hair growth when applied topically. JXL069, finasteride, and minoxidil are suggested as alternative treatments.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A user's hair regrowth journey using biotin and minoxidil after initial treatments with Nizoral shampoo and Ketoconazole serum didn't work. The comments suggest the hair loss might not be male pattern baldness (MPB), but possibly Alopecia Areata, an autoimmune disorder, and recommend getting a second opinion and considering other treatments like corticosteroids.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

A bodybuilder discusses homebrewing Minoxidil and RU58841 using propylene glycol or MCT. They inquire about the feasibility and potential risks of these methods.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The user added P5P (vitamin B6) to their shampoo to reduce scalp itch, which improved significantly. They have been using finasteride for hair loss but are exploring additional treatments like topical antiandrogens and prolactin inhibitors.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.